Oral micronized progesterone

Clinical Therapeutics

Volumn 21, Issue 1, 1999, Pages 41-60

  De Lignières, Bruno ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Artery wall vasomotility; Endometrial hyperplasia; Progesterone; Synthetic progestins

Indexed keywords

20ALPHA DIHYDROPROGESTERONE; ESTROGEN; GESTAGEN; HYDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; PREGNANEDIOL; PREGNANEDIONE; PREGNENOLONE; PROGESTERONE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BLOOD PRESSURE; CLINICAL TRIAL; DROWSINESS; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FIRST PASS EFFECT; HEMOSTASIS; HORMONAL THERAPY; HUMAN; LIPID BLOOD LEVEL; METRORRHAGIA; POSTMENOPAUSE; PROGESTERONE BLOOD LEVEL; REVIEW; SECONDARY AMENORRHEA; SOMNOLENCE; VERTIGO;

EID: 0032973272     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88267-3     Document Type: Article

References (86)

1. 1. Marcus R. New perspectives on the skeletal role of estrogen. J Clin Endocrinol Metab. 1998;83:2236-2238.
2. 2. Grodstein F, Stampfer MJ, Manson JF, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. NEJM. 1996;335:453-461.
3. 3. Grady D, Ernster VL. Hormone replacement therapy and endometrial cancer: Are current regimens safe? J Natl Cancer Inst. 1997;98:1088-1089.
4. 4. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273: 199-208.
5. 5. Chang KJ, Fournier S, Lee TTY, et al. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril. 1995;63:785-791.
6. 6. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril. 1998;69:963-969.
7. 7. Beral V, Bull D, Doll R, et al. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet. 1997;350: 1047-1059.
8. 8. Bonnier P, Romain S, Giacalone PL, et al. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol. 1995;85:11-17.
9. 9. Holli K, Isola J, Cuzik J. Hormone replacement therapy and biological aggressiveness of breast cancer. Lancet. 1997; 350:1704-1705.
10. 10. Magnusson C, Holmberg L, Norden T, et al. Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat. 1996;38:325-334.
11. 11. Salmon RJ, Remvikos Y, Ansquer Y, Asselain B. HRT and breast cancer. Lancet. 1995;346:1702-1703.
12. 12. Adams MR, Golden DL. Atheroprotective effects of estrogen replacement therapy are antagonized by medroxyprogesterone acetate in monkeys. Circulation. 1995; 92:1-627. Abstract.
13. 13. Giraud GD, Morton MJ, Wilson RA, et al. Effects of estrogen and progestin on aortic size and compliance in postmenopausal women. Am J Obstet Gynecol. 1996; 174:1708-1718.
14. 14. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 1997;3:324-327.
15. 15. Oparil S, Levine RL, Chen SJ, et al. Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment. Circulation. 1997;95:1301-1307.
16. 16. Sorensen K, Dorup I, Hermann A, Mosekide L. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation. 1998;97:1234-1238.
17. 17. Sullivan JM, Shala BA, Miller LA, et al. Progestin enhances vasoconstrictor responses in postmenopausal women receiving estrogen replacement therapy. J North Am Menopause Soc. 1995;2:193-199.
18. 18. Clarkson TB, Hughes CL, Klein KP. The nonhuman primate model of the relationship between gonadal steroids and coronary heart disease. Prog Cardiovasc Dis. 1995;38:189-198.
19. 19. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
20. 20. Lee WS, Harder JA, Yoshizumi M, et al. Progesterone inhibits arterial smooth muscle cell proliferation. Nat Med. 1997;3: 1005-1008.
21. 21. Morey AK, Pedram A, Razandi M, et al. Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology. 1997;138:3330-3339.
22. 22. Gerhard M, Walsh BW, Tawakol A, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation. 1998;98:1158-1163.
23. 23. Suvanto-Luukkonen E, Sundstrom H, Penttinen J. et al. Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy. Maturitas. 1997;26:211-217.
24. 24. Baker DA, Plotkin SA. Enhancement of vaginal infection in mice by herpes simplex virus type II with progesterone. Proc Soc Exp Biol Med. 1978;158:131-134.
25. 25. Marx PA, Spira AI, Gettie A, et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med. 1996;2:1084-1089.
26. 26. Kaushic C, Murdin A, Underdown B, Wira C. Chlamydia trachomatis infection in the female reproductive tract of the rat: Influence of progesterone on infectivity and immune response. Infect Immun. 1998;66: 893-989.
27. 27. Morville R, Dray F, Reynier J, Barrat J. Biodisponibilité de la progestérone naturelle administrée par voie orale. Mesure des concentrations du stéroïde dans le plasma, l'endomètre et le tissu mammaire. J Gynécol Obstet Biol Reprod (Paris). 1982;11:355-363.
28. 28. Barrett-Connor E, Slone S, Greendale G, et al. The Postmenopausal Estrogen/ Progestin Interventions Study: Primary outcomes in adherent women. Maturitas. 1997;27:261-274.
29. 29. Shangold MM, Zinaman TP, Tomai TP, et al. Factors associated with withdrawal bleeding after administration of oral micronized progesterone in women with secondary amenorrhea. Fertil Steril. 1991;56: 1040-1047.
30. 30. Hargrove JT, Maxson WS, Wentz AC. Absorption of oral progesterone is influenced by vehicle and particle size. Am J Obstet Gynecol. 1989;161:948-951.
31. 31. Data on file. Solvay Pharmaceuticals, Inc., Marietta, Georgia.
32. 32. Ottosson UB, Carlstrom K, Damber JE, von Schoultz B. Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parenteral administration. Br J Obstet Gynaecol. 1984;91:1111-1119.
33. 33. Simon JA, Rocci ML, Robinson DE, et al. The absorption of oral micronized progesterone: The effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil Steril. 1993;60: 26-33.
34. 34. de Lignières B, Dennerstein L, Backstrom T. Influence of route of administration on progesterone metabolism. Maturitas. 1995; 21:251-257.
35. 35. Kuhnz W, Gansau C, Mahler M. Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17b-estradiol. Arzneimittelforschung. 1993; 43:966-973.
36. 36. Norman TR, Morse CA, Dennerstein L. Comparative bioavailability of orally and vaginally administered progesterone. Fertil Steril. 1991;56:1034-1039.
37. 37. Padwick ML, Endacott J, Whitehead M. Pharmacokinetics of oral micronised progesterone. Maturitas. 1984;6:161.
38. 38. Nillius SJ, Johansson EDB. Plasma levels of progesterone after vaginal, rectal, or intramuscular administration of progesterone. Am J Obstet Gynecol. 1971;110: 470-477.
39. 39. Brenner PF. The pharmacology of progestogens. J Reprod Med. 1982;27: 490-497.
40. 40. Back DJ, Breckenridge AM, Crawford FE, et al. Kinetics of norethindrone in women. II. Single-dose kinetics. Clin Pharmacol Ther. 1978;24:448-453.
41. 41. Kuhl H, Jung-Hoffmann C, Heidt F. Serum levels of 3-keto-desogestrel and SHBG during 12 cycles of treatment with 30 meg ethinylestradiol and 150 mcg desogestrel. Contraception. 1988;38:381-390.
42. 42. Kuhnz W. Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women. Am J Obstet Gynecol. 1990;163:2120-2127.
43. 43. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol. 1994;170:1213-1223.
44. 44. Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA. 1996;275:370-375.
45. 45. de Lignières B, Moyer DL. Influence of sex hormones on hyperplasia/carcinoma risks. In: Lobo RA, ed. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. New York: Raven Press; 1994:373-383.
46. 46. Lane G, Siddle NC, Ryder TA, et al. Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium. BMJ. 1983;287:1241-1245.
47. 47. Moyer DL, de Lignières B, Driguez P, Pez JP. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: Influence of bleeding pattern and secretory changes. Fertil Steril. 1993;59:992-997.
48. 48. Foidart JM, Dombrowicz D, Roelandt L, et al. Impact on the endometrium of hormone replacement with combined progesterone and percutaneous estradiol. In: Christiansen C, Riis B, eds. Proceedings of 4th International Symposium on Osteoporosis, Hong Kong, 1993. Denmark: Aalborg ApS; 1993:331-333.
49. 49. Colvin PL Jr, Auerbach BJ, Case LD, et al. A dose-response relationship between sex hormone-induced change in hepatic triglyceride lipase and high-density lipoprotein cholesterol in postmenopausal women. Metabolism. 1991;40:1052-1056.
50. 50. Tikkanen MJ. The menopause and hormone replacement therapy: Lipids, lipoproteins, coagulation and fibrinolytic factors. Maturitas. 1996;23:209-216.
51. 51. Saarikoski DS, Yliskoski M, Penttila I. Sequential use of norethisterone and natural progesterone in pre-menopausal bleeding disorders. Maturitas. 1990;12: 89-97.
52. 52. Fahraeus L, Larsson-Cohn U, Wallentin L. I-norgestrel and progesterone have different influences on plasma lipoproteins. Eur J Clin Invest. 1983;13:447-453.
53. 53. Jensen J, Riis BJ, Stroem V, et al. Long-term effects of percutaneous oestrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol. 1987;156:66-71.
54. 54. Kauppila A, Kivinen S, Stenback F, et al. Tamoxifen and natural progesterone as supplements to low-dose postmenopausal estrogen therapy. Gynecol Obstet Invest. 1988;25:58-65.
55. 55. Lindberg UB, Crona N, Silfverstolphe G, et al. Regional adipose tissue metabolism in postmenopausal women after treatment with exogenous sex steroids. Horm Metab Res. 1990;22:345-351.
56. 56. Moorjani S, Dupont A, Labrie F, et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with Utrogestan in menopausal women. J Clin Endocrinol Metab. 1991;73:373-379.
57. 57. Mosnier-Pudar H, Faguer B, Guyenne TT, Tchobroutsky G. Effets de la substitution par 17β estradiol percutané et progestérone orale sur la pression artérielle et les paramètres métaboliques chez des patientes ménopausées diabétiques non insulinodépendantes. Arch Mal Coeur Vaiss. 1991;84:1111-1115.
58. 58. Ottosson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during oestrogen replacement therapy: A comparison between progestogens and natural progesterone. Am J Obstet Gynecol. 1985;151:746-750.
59. 59. Wagner JD, Martino MA, Jayo MJ, et al. The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal Cynomolgus monkeys. Metabolism. 1996;45:1254-1262.
60. 60. Elkind-Hirsch KE, Sherman LD, Malinak R. Hormone replacement therapy alters insulin sensitivity in young women with premature ovarian failure. J Clin Endocrinol Metab. 1993;76:472-475.
61. 61. Corvol P, Elkik F, Feneant M, et al. Effect of progesterone and progestins on water and salt metabolism. In: Bardin CW, Millgrom E, Mauvais-Jarvis P, et al, eds. Progesterone and Progestins. New York: Raven Press; 1983:1979-1986.
62. 62. Hassager C, Riis B, Strom V, et al. The long term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure. Circulation. 1987;76: 753-758.
63. 63. Dupont A, Dupont P, Cusan L, et al. Comparative endocrinological and clinical effects of percutaneous oestradiol and conjugated estrogens as replacement therapy in menopausal women. Maturitas. 1991; 13:297-311.
64. 64. Rylance PB, Brincat M, Lafferty K, et al. Natural progesterone and antihypertensive action. BMJ. 1985;290:13-14.
65. 65. de Lignières B. Progestogens in the climacteric: Mechanism of action - water, salt metabolism and blood pressure. Int Proc J. 1989;1:93-99.
66. 66. Fenichel P, Balarac N, Isetta M, et al. Effets d'une association estradiol percutané-progestérone micronisée orale sur l'hémostase en période de périménopause. Rev Francaise Gynecol Obstet. 1982;77: 93-97.
67. 67. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. Arterioscler Thromb Vasc Biol. 1997;17:3071-3078.
68. 68. Pedersen AT, Lidegaard O, Kreiner S, Ottesen B. Hormone replacement therapy and risk of non-fatal stroke. Lancet. 1997;350:1277-1283.
69. 69. Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: Population based case control study. BMJ. 1997;314:796-800.
70. 70. Lorrain J, Lalumiere G, Caron P. The effects of oral micronized progesterone on bleeding patterns, endometrial histology and bone density in postmenopausal women on hormone replacement therapy. Int J Gynaecol Obstet. 1994;46(Suppl 1):77. Poster.
71. 71. Gillet JY, Andre G, Faguer B, et al. Induction of amenorrhea during hormone replacement therapy: Optimal micronized progesterone dose. A multicenter study. Maturitas. 1994;19:103-115.
72. 72. Marengo M, Rodriguez Vidal D, Gil Deza E. Hormonal replacement therapy. Evaluation of a novel 25-day regimen with percutaneous estradiol and micronized oral progesterone. Presented at: 8th International Congress on the Menopause; November 3-7, 1996; Sydney, Australia. Abstract P299.
73. 73. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol. 1994;83:686-692.
74. 74. Hillard TC, Siddle NC, Whitehead MI, et al. Continuous combined conjugated equine estrogen-progestogen therapy: Effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis. Am J Obstet Gynecol. 1992;167:1-7.
75. 75. Ettinger B, Li DK, Klein R. Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy: Comparison of cyclic versus continuous combined schedules. Fertil Steril. 1998; 69:865-869.
76. 76. Habiba MA, Bell SC, Abrams K, Al Azzawi F. Endometrial responses to hormone replacement therapy: The bleeding pattern. Hum Reprod. 1987;76:753-758.
77. 77. Saure A, Hirvonen E, Mislom I, et al. A randomized, double-blind, multicenter study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms. Maturitas. 1996;24:111-118.
78. 78. Torry DS, Holt VJ, Keenan JA, et al. Vascular endothelial growth factor expression in cycling human endometrium. Fertil Steril. 1998;66:72-80.
79. 79. Tapanainen J, Kauppila A, Metsa-Ketela T, Vapaatalo H. Prostanoids and catecholamines after oral administration of natural progesterone. Gynecol Endocrinol. 1989;3:135-142.
80. 80. Dennerstein L, Spencer-Gardner C, Gotts G, et al. Progesterone and the premenstrual syndrome: A double-blind crossover trial. BMJ. 1985;290:1617-1621.
81. 81. Magos AL, Brewster E, Singh R, et al. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: A model for the premenstrual syndrome. Br J Obstet Gynaecol. 1986;93:1290-1296.
82. 82. de Lignières D, Vincens M. Differential effects of exogenous oestradiol and progesterone on mood in post-menopausal women: Individual dose/effect relationship. Maturitas. 1982;4:67-72.
83. 83. Erny R, Pigne A, Prouvost C, et al. The effects of oral administration of progesterone for premature labor. Am J Obstet Gynecol. 1986;154:525-529.
84. 84. Noblot G, Audra P, Dargent D, et al. The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynaecol Reprod Biol. 1991;40:203-209.
85. 85. Benifla JL, Dumont M, Levardon M, et al. Effets de la progestérone naturelle micronisée sur le foie au cours du troisième trimestre de la grossesse. Contracept Fertil Sex (Paris). 1997;25:165-169.
86. 86. Bacq Y, Sapey T, Brechot MC, et al. Intrahepatic cholestasis of pregnancy: A French prospective study. Hepatology. 1997;26:358-364.